Graviton Enters into Global Licensing Agreement for ROCK2 Inhibitor from Beijing TidePRNewsWire • 02/23/21
MeiraGTx To Present Clinical Program Update for AAV-hAQP1 Treatment of Radiation-Induced XerostomiaGlobeNewsWire • 12/16/20
MeiraGTx to Participate in the Piper Sandler 32nd Annual Virtual Healthcare ConferenceGlobeNewsWire • 11/23/20
MeiraGTx Announces Investigational Gene Therapy Continues to Demonstrate Statistically Significant Improvement in Vision in Patients with X-Linked Retinitis Pigmentosa One Year After TreatmentGlobeNewsWire • 11/13/20
MeiraGTx Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa to be Presented at AAO 2020 Virtual MeetingGlobeNewsWire • 10/28/20
MeiraGTx Announces Nine-Month Data from Phase 1/2 Trial of AAV-RPGR Demonstrating Significant and Sustained Vision Improvement in X-Linked Retinitis Pigmentosa (XLRP)GlobeNewsWire • 10/03/20
MeiraGTx Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa to be Presented at EURETINA 2020 Virtual MeetingGlobeNewsWire • 09/22/20
MeiraGTx Is A Buy With Multiple Near-Term Catalysts As The Stock Is Weighed Down By Negative SentimentSeeking Alpha • 08/24/20
MeiraGTx Announces Positive Clinical Data Demonstrating Treatment with AAV-RPGR Investigational Gene Therapy Improves Vision in X-Linked Retinitis Pigmentosa Patients GlobeNewsWire • 07/17/20
MeiraGTx Holdings PLC (MGTX) Moves to Strong Buy: Rationale Behind the UpgradeZacks Investment Research • 06/26/20
MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked Retinitis PigmentosaGlobeNewsWire • 03/02/20
What Makes MeiraGTx Holdings PLC (MGTX) a Strong Momentum Stock: Buy Now?Zacks Investment Research • 12/24/19